Literature DB >> 1593604

Dismantling the pyramid.

J E Levinson1, C A Wallace.   

Abstract

The suggestion is heard, with increasing frequency, that the therapeutic pyramid be dismantled and that medical management be reordered to treat juvenile rheumatoid arthritis as early and as decisively as possible to induce prompt remission of disease, thereby preserving function and the quality of life. We scrutinize paradigms that guide our treatment strategies, review current practices, update data derived from those practices, and propose reassessment for treatment in the 1990s.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593604

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  14 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment.

Authors:  Rabina Kochar; Kyle M Walsh; Anil Jain; Steven J Spalding; Philip J Hashkes
Journal:  Rheumatol Int       Date:  2011-09-11       Impact factor: 2.631

3.  Pediatric rheumatology: Strengths and challenges of a new guide for treating JIA.

Authors:  Philip J Hashkes
Journal:  Nat Rev Rheumatol       Date:  2011-05-17       Impact factor: 20.543

Review 4.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

Review 5.  Advances and challenges in imaging in juvenile idiopathic arthritis.

Authors:  Silvia Magni-Manzoni; Clara Malattia; Stefano Lanni; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2012-03-27       Impact factor: 20.543

Review 6.  Management of childhood arthritis. Part 2: Chronic arthritis.

Authors:  P N Malleson
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

7.  Adalimumab for juvenile idiopathic arthritis-associated uveitis.

Authors:  Adriano Magli; Raimondo Forte; Pasqualina Navarro; Giustina Russo; Francesca Orlando; Loredana Latanza; Maria Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-01       Impact factor: 3.117

8.  Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial.

Authors:  Ruy Carrasco; Daniel J Lovell; Edward H Giannini; Carol J Henderson; Bin Huang; Sandy Kramer; Julie Ranz; James Heubi; David Glass
Journal:  Arthritis Rheum       Date:  2008-12

Review 9.  Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?

Authors:  E H Giannini; J T Cassidy
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

10.  Abatacept in difficult-to-treat juvenile idiopathic arthritis.

Authors:  Jasmin B Kuemmerle-Deschner; Sm Benseler
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.